share_log

ShanXi C&Y Pharmaceutical Group (SZSE:300254) Delivers Shareholders Notable 54% Return Over 1 Year, Surging 18% in the Last Week Alone

ShanXi C&Y Pharmaceutical Group (SZSE:300254) Delivers Shareholders Notable 54% Return Over 1 Year, Surging 18% in the Last Week Alone

山西C&Y药业集团(深交所代码:300254)在1年内为股东带来了可观的54%的回报,仅在上周就飙升了18%
Simply Wall St ·  2023/10/31 21:27

If you want to compound wealth in the stock market, you can do so by buying an index fund. But investors can boost returns by picking market-beating companies to own shares in. To wit, the ShanXi C&Y Pharmaceutical Group Co., Ltd. (SZSE:300254) share price is 54% higher than it was a year ago, much better than the market decline of around 0.9% (not including dividends) in the same period. So that should have shareholders smiling. Having said that, the longer term returns aren't so impressive, with stock gaining just 23% in three years.

如果你想在股票市场上增加财富,你可以通过购买指数基金来实现。但是投资者可以通过选择领先市场的公司来持有股票来提高回报。也就是说, 山西晨源药业集团有限公司 深交所股票代码:300254)的股价比去年同期上涨了54%,远好于同期约0.9%(不包括股息)的市场跌幅。因此,这应该让股东们微笑。话虽如此,长期回报并不那么可观,股票在三年内仅上涨了23%。

After a strong gain in the past week, it's worth seeing if longer term returns have been driven by improving fundamentals.

在过去一周强劲上涨之后,值得一看的是长期回报是否是由基本面改善推动的。

See our latest analysis for ShanXi C&Y Pharmaceutical Group

查看我们对山西C&Y药业集团的最新分析

Because ShanXi C&Y Pharmaceutical Group made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. When a company doesn't make profits, we'd generally expect to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

由于山西C&Y药业集团在过去十二个月中出现了亏损,我们认为市场可能更加关注收入和收入增长,至少目前是如此。当一家公司没有盈利时,我们通常会看到良好的收入增长。可以想象,快速的收入增长如果得以维持,通常会带来快速的利润增长。

ShanXi C&Y Pharmaceutical Group actually shrunk its revenue over the last year, with a reduction of 9.4%. Despite the lack of revenue growth, the stock has returned a solid 54% the last twelve months. We can correlate the share price rise with revenue or profit growth, but it seems the market had previously expected weaker results, and sentiment around the stock is improving.

山西C&Y药业集团去年实际上缩减了收入,下降了9.4%。尽管收入缺乏增长,但该股在过去十二个月中仍稳步回报了54%。我们可以将股价上涨与收入或利润增长关联起来,但市场此前似乎预计业绩将疲软,围绕该股的情绪正在改善。

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

您可以在下面看到收入和收入如何随着时间的推移而变化(点击图片了解确切的值)。

earnings-and-revenue-growth
SZSE:300254 Earnings and Revenue Growth November 1st 2023
深交所:300254 2023年11月1日的收益和收入增长

Take a more thorough look at ShanXi C&Y Pharmaceutical Group's financial health with this free report on its balance sheet.

用这个更全面地了解山西C&Y药业集团的财务状况 免费的 在其资产负债表上报告。

A Different Perspective

不同的视角

It's nice to see that ShanXi C&Y Pharmaceutical Group shareholders have received a total shareholder return of 54% over the last year. That's better than the annualised return of 9% over half a decade, implying that the company is doing better recently. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. It's always interesting to track share price performance over the longer term. But to understand ShanXi C&Y Pharmaceutical Group better, we need to consider many other factors. Even so, be aware that ShanXi C&Y Pharmaceutical Group is showing 2 warning signs in our investment analysis , and 1 of those is a bit concerning...

很高兴看到山西C&Y药业集团的股东在去年获得了54%的股东总回报率。这比五年来9%的年化回报率要好,这意味着该公司最近的表现更好。持乐观观点的人可能会将最近股东总回报率的改善视为业务本身随着时间的推移而变得越来越好。从长远来看,追踪股价表现总是很有意思的。但是,为了更好地了解山西C&Y药业集团,我们需要考虑许多其他因素。即便如此,请注意,山西C&Y药业集团正在展出 我们的投资分析中有两个警告信号 ,其中 1 个有点令人担忧...

But note: ShanXi C&Y Pharmaceutical Group may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

但请注意: 山西C&Y药业集团可能不是最值得买入的股票。所以来看看这个 免费的 过去盈利增长(以及进一步增长预测)的有趣公司名单。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

请注意,本文引用的市场回报反映了目前在中国交易所交易的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?担心内容吗? 取得联系 直接和我们在一起。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St 的这篇文章本质上是笼统的。 我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。 它不构成买入或卖出任何股票的建议,也没有考虑您的目标或财务状况。我们的目标是为您提供由基本面数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。简而言之,华尔街在上述任何股票中都没有头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发